{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021739","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.556637+00:00","generated_at":"2026-06-22T09:19:02.609253+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kezar Life Sciences reports positive MISSION Phase 2 results: 64.7% ORR at Week 25, increases to 94.1% in follow-up","bullets":["ORR (≥50% proteinuria reduction) in 11/17 patients (64.7%) at Week 25; increased to 94.1% at Week 29 and 88.2% at Week 37.","CRR (UPCR ≤0.5) achieved in 35.3% at end of treatment, rising to 41.2% during safety follow-up (Week 29 & 37).","Mean background corticosteroid use reduced by 53%; by Week 13, 82.4% on ≤10 mg/day steroids.","SLEDAI-2K reduced from 11.3 baseline to 6.5 at EOT; Physician Global Assessment from 57.2 to 23.9.","Zetomipzomib well-tolerated; no Grade 3 infections; early terminations in 4/21 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021739","json":"https://secwatch.observer/filing/0000950170-22-021739.json","markdown":"https://secwatch.observer/filing/0000950170-22-021739.md","text":"https://secwatch.observer/filing/0000950170-22-021739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022021739/0000950170-22-021739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022021739/kzr-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:19:02.609253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}